Regional News

Year: Display by: Sort
January 2016
FDA Approves New Oral Therapy for ALK-Positive Lung Cancer

The FDA has approved alectinib (Alecensa, Genentech) to treat patients with advanced (metastatic) anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate, treatment with ...

Last Updated: January 27, 2016 | Posted on: January 04, 2016
Immunology Bests Chemo in Lung Cancer Study

A new study adds to the evidence that immunology is superior to chemotherapy in the treatment of lung cancer. Lung cancer is the leading cause of cancer deaths worldwide; the American Lung Association estimates more than 158,000 people in the U.S. will ...

Posted on: January 04, 2016
Lilly's Lung-Cancer Drug Portrazza to Cost $11,430 a Month

Eli Lilly & Co. said its new lung-cancer drug will cost about $11,430 a patient a month in the U. S. - well above what a group of doctors say is a fair price that reflects what they call the drug's modest benefit. A Lilly spokeswoman said the price ...

Posted on: January 04, 2016
Lung Cancer More Aggressive in Younger Patients, Study Finds

Scientists at Dana-Farber Cancer Institute in Boston found non-small cell lung cancer (NSCLC) - the most common type of lung cancer and one that can metastasize to other parts of the body - is a distinct disease in younger people, genetically and ...

Posted on: January 04, 2016
Merck CEO: Major Breakthrough in Lung Cancer Treatment

During an interview with the FOX Business Network's Maria Bartiromo, Merck CEO Kenneth Frazier said the company has found, based on new data recently released, how its immune therapy drug Keytruda may help to fight advanced lung cancer. "This is a new ...

Posted on: January 04, 2016
 
 
 

Back to Top

© 2016 Merion Matters

2900 Horizon Drive, King of Prussia PA 19406

800-355-5627